Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities | |
| 10/18/2024 | Buy → Hold | Argus | ||
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | ||
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein | |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen | |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies | |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler | |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities |
Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:MOH) with a Overweight and maintains $406 price target.
Builds On Ongoing Collaboration With Google Health To Develop Population Health Solutions And Address Healthcare Challenges
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
SC 13G - CENTENE CORP (0001071739) (Subject)
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
PEMBROKE PINES, Fla., Nov. 7, 2024 /PRNewswire/ -- Sunshine Health, Florida's largest managed care organization and a Centene Corporation company (NYSE:CNC), announced today Charlene Zein has been named Plan President and Chief Executive Officer, effective Nov. 3, 2024. Zein has nearly two decades of experience in the healthcare industry, including various leadership roles of increasing scope and responsibility at Sunshine Health since joining in 2019. She most recently served as Sunshine Health Chief Product President, where she had oversight of all of Sunshine Health's Medi
Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe
Total revenues for the third quarter 2024 increased 30% to $63.7 billionShareholders' net income for the third quarter 2024 was $0.7 billion, or $2.63 per shareAdjusted income from operations1 for the third quarter 2024 was $2.1 billion, or $7.51 per shareReaffirms 2024 outlook2 for adjusted income from operations1,2 of at least $28.40 per shareBLOOMFIELD, Conn., Oct. 31, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong third quarter 2024 results demonstrating focused execution across Evernorth Health Services and Cigna Healthcare. "Ou
Reports 3Q24 earnings per share (EPS) of $3.98 on a GAAP basis, Adjusted EPS of $4.16; reports YTD 2024 EPS of $15.72 on a GAAP basis, $18.35 on an Adjusted basis Updates FY 2024 EPS guidance to 'at least $12.89' on a GAAP basis, 'at least $16.00' on an Adjusted basis; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent Raises 2024 individual Medicare Advantage annual membership growth by 40,000 to now anticipate annual growth of approximately 265,000, or approximately 5 percent Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9:00 a.m. ET question and answer session to discuss its financial results for
-- Diluted EPS of $1.36; Adjusted Diluted EPS of $1.62 -- -- Reaffirms 2024 Adjusted Diluted EPS Guidance Floor of Greater Than $6.80 -- Adjusted diluted EPS of $1.62 in the third quarter of 2024.Premium and service revenues of $36.9 billion in the third quarter of 2024.Membership increases of 22% in Marketplace and 49% in Medicare Prescription Drug Plans, compared to the third quarter of 2023.Continued execution on capital deployment with $1.2 billion of share repurchases during the third quarter of 2024 and an additional $380 million in October, bringing full-year repurchases to $2.4 billion through October 2024.ST. LOUIS, Oct. 25, 2024 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
4 - Cigna Group (0001739940) (Issuer)
4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
Argus downgraded Elevance Health from Buy to Hold
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced the closing of its previously announced offering of $750 million aggregate principal amount of 6.250% senior notes due 2033 (the "Notes") sold in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain persons outside the United States in reliance on Regulation S under the Securities Act. The Notes bear interest at a rate of 6.250% per annum. Interest on the Notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2025, and accrues from N
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced that it priced $750 million aggregate principal amount of its 6.250% senior notes due 2033 (the "Notes") to be sold in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain persons outside the United States in reliance on Regulation S under the Securities Act. The offering is expected to close on or about November 18, 2024 (such actual closing date, the "Settlement Date"), subject to the satisfaction of customary closing conditions. The Notes will not be guaranteed by any of the C
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced that it intends to privately offer, subject to market and other conditions, $500 million aggregate principal amount of senior notes due 2033 (the "Notes"). The Company will make the offering pursuant to an exemption under the Securities Act of 1933, as amended (the "Securities Act"). The initial purchasers will sell the Notes only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act and to certain persons outside the United States in reliance on Regulation S under the Securities Act ("Regulation S"). The Notes will not be guaranteed by any of the Company's sub